<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:yandex="http://news.yandex.ru" xmlns:media="http://search.yahoo.com/mrss/" xmlns:turbo="http://turbo.yandex.ru"><channel><title>Health care on Logotyp.us</title><link>https://logotyp.us/tags/health-care/</link><description>Recent content in Health care on Logotyp.us</description><generator>Hugo -- gohugo.io</generator><language>en-us</language><lastBuildDate>Sun, 18 Jul 2021 00:32:00 +0000</lastBuildDate><atom:link href="https://logotyp.us/tags/health-care/index.xml" rel="self" type="application/rss+xml"/><item turbo="true"><turbo:content>
&lt;! [CDATA[<header><h1>Novo Nordisk Logo</h1><figure><img src="https://logotyp.us/files/novo-nordisk.svg"/></figure></header>
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, with production facilities in eight countries, and affiliates or offices in 5 countries. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 25% of its shares and a supermajority of its voting shares. Novo Nordisk manufactures and markets pharmaceutical products and services specifically diabetes care medications and devices. Novo Nordisk is also involved with hemostasis management, growth hormone therapy and hormone replacement therapy.<p>You can download theNovo Nordisklogo on full-version of the page.</p>
]] ></turbo:content><image turbo="true"><url>https://logotyp.us/files/novo-nordisk.svg</url><title>Novo NordiskLogo</title><link>https://www.w3schools.com</link></image><title turbo="true">Novo Nordisk</title><link turbo="true">https://logotyp.us/logo/novo-nordisk/</link><pubDate>Sun, 18 Jul 2021 00:32:00 +0000</pubDate><guid>https://logotyp.us/logo/novo-nordisk/</guid><description turbo="true">Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, with production facilities in eight countries, and affiliates or offices in 5 countries. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 25% of its shares and a supermajority of its voting shares. Novo Nordisk manufactures and markets pharmaceutical products and services specifically diabetes care medications and devices. Novo Nordisk is also involved with hemostasis management, growth hormone therapy and hormone replacement therapy.</description></item></channel></rss>